Sentinel Lymph Node Biopsy With or Without Para-Sentinel Lymph Node Dissection in Breast Cancer
Sentinel Lymph Node Biopsy With or Without Para-Sentinel Lymph Node Dissection in Breast Cancer
Sentinel lymph node biopsy（SLNB） is an established way of predicting axillary nodal
 metastasis in early breast cancer. We aim to determinethe，in a prospective randomized,
 controlled trial, effect of sentinel lymph node biopsy with para-sentinel lymph node(SLN)
 dissection versus sentinel lymph node biopsy without para-sentinel lymph node dissection on
 outcomes after breast surgery.
Aim: Compare the disease-free survival (DFS) and overall survival (OS) of breast cancer
 patients who are randomized to receive sentinel lymph node biopsy with para-sentinel lymph
 node dissection group vs. those receive only sentinel lymph node biopsy without para-sentinel
 lymph node dissection

 Outline:

 Patients are randomized assigned to the following one of two groups and are followed
 annually.

 Arm I: Patients receive sentinel lymph node biopsy with para-sentinel lymph node dissection
 Arm II: Patients receive only sentinel lymph node biopsy without para-sentinel lymph node
 dissection
Inclusion Criteria:

 1. histologically confirmed primary breast cancer by core needle biopsy or excisional
 biopsy

 2. abnormal para-sentinel lymph node was found by ultrasound examination

 3. ultrasound-guided fine needle aspiration cytology of these nodes were performed

 4. the result of fine needle aspiration cytology was negative (no tumour cell was found)

 5. patient planed to perform SLNB

 Exclusion Criteria:

 1. pathological diagnosed ductal carcinoma in situ by excisional biopsy

 2. the result of fine needle aspiration cytology was positive

 3. patient has received neo-adjuvant system therapy